A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma

Pieter Sonneveld, Meletios A. Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Niels W.C.J. van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda Balari, Laura Rosiñol, Michel Delforge, Wilfried Roeloffzen, Tobias Silzle, Annette Vangsted, Hermann Einsele, Andrew Spencer, Roman Hajek, Artur Jurczyszyn, Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M.J. van Brummelen, Veronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodriguez-Otero, Joan Bladé, Philippe Moreau

Open source

DOI: 10.1080/14796694.2024.2394323
Published: 2024-09-17
Container: Future Oncology
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2024.2394323,
  title = {A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma},
  author = {Pieter Sonneveld and Meletios A. Dimopoulos and Mario Boccadoro and Hang Quach and P. Joy Ho and Meral Beksac and Cyrille Hulin and Elisabetta Antonioli and Xavier Leleu and Silvia Mangiacavalli and Aurore Perrot and Michele Cavo and Angelo Belotti and Annemiek Broijl and Francesca Gay and Roberto Mina and Niels W.C.J. van de Donk and Eirini Katodritou and Fredrik Schjesvold and Anna Sureda Balari and Laura Rosiñol and Michel Delforge and Wilfried Roeloffzen and Tobias Silzle and Annette Vangsted and Hermann Einsele and Andrew Spencer and Roman Hajek and Artur Jurczyszyn and Sarah Lonergan and Tahamtan Ahmadi and Yanfang Liu and Jianping Wang and Diego Vieyra and Emilie M.J. van Brummelen and Veronique Vanquickelberghe and Anna Sitthi-Amorn and Carla J. de Boer and Robin Carson and Paula Rodriguez-Otero and Joan Bladé and Philippe Moreau},
  year = {2024},
  journal = {Future Oncology},
  doi = {10.1080/14796694.2024.2394323},
  url = {https://doi.org/10.1080/14796694.2024.2394323}
}

RIS

TY  - JOUR
TI  - A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma
AU  - Pieter Sonneveld
AU  - Meletios A. Dimopoulos
AU  - Mario Boccadoro
AU  - Hang Quach
AU  - P. Joy Ho
AU  - Meral Beksac
AU  - Cyrille Hulin
AU  - Elisabetta Antonioli
AU  - Xavier Leleu
AU  - Silvia Mangiacavalli
AU  - Aurore Perrot
AU  - Michele Cavo
AU  - Angelo Belotti
AU  - Annemiek Broijl
AU  - Francesca Gay
AU  - Roberto Mina
AU  - Niels W.C.J. van de Donk
AU  - Eirini Katodritou
AU  - Fredrik Schjesvold
AU  - Anna Sureda Balari
AU  - Laura Rosiñol
AU  - Michel Delforge
AU  - Wilfried Roeloffzen
AU  - Tobias Silzle
AU  - Annette Vangsted
AU  - Hermann Einsele
AU  - Andrew Spencer
AU  - Roman Hajek
AU  - Artur Jurczyszyn
AU  - Sarah Lonergan
AU  - Tahamtan Ahmadi
AU  - Yanfang Liu
AU  - Jianping Wang
AU  - Diego Vieyra
AU  - Emilie M.J. van Brummelen
AU  - Veronique Vanquickelberghe
AU  - Anna Sitthi-Amorn
AU  - Carla J. de Boer
AU  - Robin Carson
AU  - Paula Rodriguez-Otero
AU  - Joan Bladé
AU  - Philippe Moreau
PY  - 2024
JO  - Future Oncology
DO  - 10.1080/14796694.2024.2394323
UR  - https://doi.org/10.1080/14796694.2024.2394323
ER  -

APA

Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., Perrot, A., Cavo, M., Belotti, A., Broijl, A., Gay, F., Mina, R., Donk, N. W. V. D., Katodritou, E., Schjesvold, F., Balari, A. S., Rosiñol, L., Delforge, M., Roeloffzen, W., Silzle, T., Vangsted, A., Einsele, H., Spencer, A., Hajek, R., Jurczyszyn, A., Lonergan, S., Ahmadi, T., Liu, Y., Wang, J., Vieyra, D., Brummelen, E. M. V., Vanquickelberghe, V., Sitthi-Amorn, A., Boer, C. J. D., Carson, R., Rodriguez-Otero, P., Bladé, J., & Moreau, P. (2024). A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma. Future Oncology. https://doi.org/10.1080/14796694.2024.2394323

Source records

crossref · retrieved 2026-09-27T04:07:18.859Z